Stock Analiz

Novartis AG (NVS) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Novartis’s revenue went from $48.5B in fiscal 2016 to $54.5B in fiscal 2025, growth of about 1.3% a year.

Net income in fiscal 2025 was $14.0B, a net margin of 25.6%; the best year in this period was 2021 with $24.0B.

Over the twelve months to September 30, 2026, revenue was $57.4B and net income $10.0B.

Free cash flow was $17.6B in fiscal 2025 and positive in 10 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $48.5B162017: $42.4B172018: $44.8B182019: $47.5B192020: $48.7B202021: $42.8B212022: $42.2B222023: $45.4B232024: $50.3B242025: $54.5B25$54.5B
Net income
2016: $6.7B162017: $7.7B172018: $12.6B182019: $11.7B192020: $8.1B202021: $24.0B212022: $7.0B222023: $14.8B232024: $11.9B242025: $14.0B25$14.0B
Free cash flow
2016: $9.6B162017: $11.3B172018: $13.0B182019: $12.2B192020: $12.4B202021: $14.0B212022: $13.3B222023: $13.4B232024: $16.3B242025: $17.6B25$17.6B
EPS (diluted)
2016: $3.52162017: $4.04172018: $6.61182019: $6.15192020: $4.23202021: $12.59212022: $3.64222023: $7.78232024: $6.26242025: $7.3325$7.33

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$57.4B$54.5B$50.3B$45.4B$42.2B$42.8B$48.7B$47.5B$44.8B$42.4B$48.5B
Gross profit—$43.0B$38.9B$34.2B$31.9B$32.2B$34.8B$34.3B$31.6B$29.8B$31.9B
Operating income—$17.6B$14.5B$9.8B$7.9B$10.1B$10.2B$9.1B$8.4B$8.7B$8.3B
Net income$10.0B$14.0B$11.9B$14.8B$7.0B$24.0B$8.1B$11.7B$12.6B$7.7B$6.7B
EPS (diluted)$5.23$7.33$6.26$7.78$3.64$12.59$4.23$6.15$6.61$4.04$3.52
R&D———————————
Revenue growth—+8.4%+10.7%+7.7%−1.3%−12.1%+2.4%+5.9%+5.8%−12.7%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$17.3B$19.1B$17.6B$14.5B$14.2B$15.1B$13.7B$13.6B$14.3B$12.6B$11.5B
Capital spending-$3.3B-$1.5B-$1.4B-$1.1B-$916M-$1.1B-$1.3B-$1.4B-$1.3B-$1.3B-$1.9B
Free cash flow$14.0B$17.6B$16.3B$13.4B$13.3B$14.0B$12.4B$12.2B$13.0B$11.3B$9.6B
Dividends paid$9.1B$7.8B$7.6B$7.3B$7.5B$7.4B$7.0B$6.6B$7.0B$6.5B$6.5B
Buybacks—$9.2B$8.3B$8.7B$10.7B$3.1B$2.8B$5.5B$2.0B$5.5B$1.1B
Stock-based pay—$1.1B$1.0B$865M$791M$700M$738M$758M$673M$612M$671M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$11.4B$11.5B$13.4B$7.5B$12.4B$9.7B$11.1B$13.3B$8.9B$7.0B
Debt—$28.7B$24.7B$20.6B$22.5B$25.5B$28.5B$22.4B$25.7B$23.6B—
Equity—$46.1B$44.0B$46.7B$59.3B$67.7B$56.6B$55.5B$78.6B$74.2B$74.9B
Total assets—$110.9B$102.2B$99.9B$117.5B$131.8B$127.8B$118.4B$145.6B$133.1B—
Shares (diluted)1.92B1.91B1.91B1.91B1.91B1.91B1.91B1.91B1.91B1.91B1.91B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—78.8%77.3%75.2%75.5%75.4%71.5%72.1%70.5%70.2%65.8%
Operating margin—32.4%28.9%21.5%18.8%23.5%20.9%19.1%18.7%20.5%17.0%
Net margin17.5%25.6%23.7%32.7%16.5%56.1%16.6%24.7%28.1%18.2%13.8%
FCF margin24.4%32.3%32.3%29.5%31.6%32.7%25.4%25.8%29.0%26.7%19.8%
ROIC—20.1%18.5%13.6%8.2%10.1%9.7%9.3%7.3%7.3%9.5%
ROE—30.3%27.1%31.8%11.7%35.5%14.3%21.1%16.0%10.4%9.0%

Frequently asked questions

What is Novartis’s annual revenue?

$54.5B in fiscal 2025 and $57.4B over the twelve months to September 30, 2026.

How much profit does Novartis make?

Net income was $14.0B in fiscal 2025 (net margin 25.6%).

Is Novartis’s revenue growing?

Yes: revenue rose 8.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.